releases: https://www.hawley.senate.gov/hawley-urges-rfk-jr-to-reinstate-safety-regulations-on-chemical-abortion-drug-after-reviewing-studies/
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://www.hawley.senate.gov/hawley-urges-rfk-jr-to-reinstate-safety-regulations-on-chemical-abortion-drug-after-reviewing-studies/ | Hawley Urges RFK Jr. to Reinstate Safety Regulations on Chemical Abortion Drug after Reviewing Studies | 2025-07-22 | 2025 | 2025-07 | Republican | Senate | MO | Josh Hawley | H001089 | www.hawley.senate.gov | hawley | https://www.hawley.senate.gov/press-releases/page/ | scraper | Today, U.S. Senator Josh Hawley (R-Mo.) sent a letter to Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. (RFK Jr.) urging him to take immediate action to reinstate safety guardrails on the chemical abortion drug mifepristone. Senator Hawley’s letter comes after he secured a pledge from RFK Jr. that he would conduct a safety review of mifepristone. “I write to thank you for your expressed commitment to review the safety data on mifepristone following the publication of alarming new safety studies and to once again request swift action on this matter to protect American women. On April 28, I sent a letter to Food and Drug Administration (FDA) Commissioner, Dr. Marty Makary, asking for a timely review of the safety of mifepristone in response to shocking new data showing high adverse event rates for mifepristone. Dr. Makary sent me a letter in response expressing a commitment to conducting such a review. I am grateful to both you and Dr. Makary for undertaking this critical work,” Senator Hawley wrote. He continued, “As I have shared with you, recent studies using insurance claims data to conduct post-market safety analyses have raised serious concerns about the chemical abortion drug. Researchers with the Foundation for the Restoration of America and Ethics and Public Policy Center found that about 11% of women who take mifepristone for an abortion experience a serious adverse health event—a rate 22 times higher than the FDA claims. Additionally, a follow-up Ethics and Public Policy Center study based on the same data shows that for pregnancy termination, mifepristone had a 5.26% failure rate, which is significantly higher than the rate listed on the FDA label.” Senator Hawley concluded, “I eagerly await the results of your review of mifepristone safety data… I ask that you take swift action against abortion drug providers that distribute mifepristone contrary to federal regulations. These actions would go a long way toward protecting women’s health and safety.” Read the full letter here or below. | 1 | 2026-03-30T01:40:41Z | 2026-04-06T18:48:13Z |